Company Filing History:
Years Active: 2001
Title: David Givol: Innovator in Monoclonal Antibodies
Introduction
David Givol is a notable inventor based in Rehovot, Israel. He is recognized for his significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for cancer treatment and therapeutic methods.
Latest Patents
David Givol holds a patent for "Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same." This patent describes hybridoma cell lines that produce monoclonal antibodies capable of inhibiting the growth of human tumor cells expressing the human epidermal growth factor receptors. The therapeutic uses of these antibodies, both alone and in combination with anti-neoplastic agents, are also detailed in the patent.
Career Highlights
Throughout his career, David Givol has worked with prominent companies in the biotechnology sector, including Rhone-Poulenc Rorer International (Holdings), Inc. and Rorer International Inc. His expertise in monoclonal antibodies has positioned him as a key figure in the development of innovative cancer therapies.
Collaborations
David Givol has collaborated with esteemed colleagues such as Joseph Schlessinger and Francoise Bellot. These partnerships have furthered research and development in the field of monoclonal antibodies.
Conclusion
David Givol's contributions to the field of biotechnology, particularly through his patent on monoclonal antibodies, highlight his role as an innovator in therapeutic methods for cancer treatment. His work continues to influence advancements in medical science.